Conference Coverage

Comorbid spondyloarthritis and fibromyalgia lower response to TNF inhibitors


 

REPORTING FROM RHEUMATOLOGY 2018


The BSRBR-AS is funded by the British Society for Rheumatology, which in turn receives funding from AbbVie, Pfizer, and UCB. Dr. Macfarlane did not provide any disclosures but has previously acknowledged receiving an honorarium from Pfizer and research funding from AbbVie and Pfizer for the Scotland Registry for Ankylosing Spondylitis study.

SOURCE: Macfarlane GJ et al. Rheumatology. 2018;57(Suppl. 3):key075.183.

Pages

Recommended Reading

VIDEO: Beware of over-relying on MRI findings in axSpA
MDedge Family Medicine
Flare of nonradiographic axial SpA occurs often after adalimumab withdrawal for remission
MDedge Family Medicine
Testing for latent tuberculosis infection
MDedge Family Medicine
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications
MDedge Family Medicine
Arthritis limits physical activity the most in the South
MDedge Family Medicine
Maternal biologic therapy does not affect infant vaccine responses
MDedge Family Medicine
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Family Medicine
Axial SpA disease activity remains mostly stable throughout pregnancy
MDedge Family Medicine
TB in 2017: Good news and bad news
MDedge Family Medicine
MACE risk similar across arthritis subtypes
MDedge Family Medicine